Celemics, Inc.
KKRX:3319209,980.00
KRW
-90.00
(-0.89%)
ISIN
KR7331920009
Return %
Stock
S&P 500
1Y
229.92
14.20
3Y
209.46
81.12
5Y
-36.84
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 41
- Sector
- Electronic technology
- Industry
- Electronic equipment/Instruments
- Address
- Seoul South Korea
- IPO Date
- Aug 21, 2020
- Website
- celemics.com
- Similar Companies
- Business
- Celemics, Inc. is a South Korea-based biotechnology company that develops, manufactures, and commercializes next-generation sequencing (NGS) target enrichment solutions, synthetic biology platforms, and bioinformatics tools for clinical diagnostics, life science research, and biopharmaceutical applications. Founded in 2010 and headquartered in Seoul, South Korea, with international branches and distribution networks across North America, Europe, and Asia, the company serves academic institutions, clinical laboratories, hospitals, and biopharmaceutical enterprises worldwide. The company's core offerings encompass ready-to-use targeted sequencing panels, including CancerScreen oncology assays for somatic mutation and liquid biopsy circulating tumor DNA (ctDNA) analysis, G-Mendeliome panels for inherited genetic disorders, PharmacoScreen panels for pharmacogenomics, and targeted panels for infectious disease and pathogen detection; custom NGS hybridization-capture panel design, probe synthesis, and sequencer-specific assay optimization services; NGS workflow reagents and consumables, such as library preparation kits, cDNA synthesis kits, hybridization enhancers, and magnetic purification beads; Barcode-Tagged Sequencing (BTSeq) technology, a proprietary NGS methodology serving as a high-throughput alternative to Sanger sequencing for sequencing DNA fragments from 200 bp to 20 kb without primer walking; TrueRepertoire, a high-throughput antibody library and immune repertoire profiling platform; and the Celemics Analysis Service (CAS) bioinformatics platform, which provides automated primary, secondary, and tertiary variant interpretation and clinical reporting. In recent developments, Celemics has expanded its strategic collaborations, including the advancement of its partnership with Strand Life Sciences to integrate Celemics hybrid-capture kits with the StrandOmics tertiary analysis platform to deliver unified sample-to-report clinical diagnostic workflows across Asia and Europe. The company has also continued the commercial rollout of specialized panels, such as hybrid capture-based respiratory pathogen surveillance assays, capitalized on diagnostic advancements alongside strategic liquid biopsy investments, and implemented executive and operational realignments to accelerate international market penetration and drive commercial scalability.